Article Highlights
Baseline insulin secretion, quantified as phi-total using the Oral Minimal Model (OMM), serves as a critical biomarker for identifying individuals with Stage 1 Type 1 Diabetes (T1D) who are most likely to respond to costimulation inhibition.
In the high-secretor subgroup, abatacept therapy resulted in a 15.8-month delay in progression to Stage 2 or 3 T1D compared to placebo, with a 54% reduction in the hazard of progression (HR 0.46).
